Lilly's Foundayo significantly reduced obstructive sleep apnea severity in Phase 3
FROM THE WIRE · FINANCE.YAHOO.COM
In adults with moderate-to-severe OSA and obesity or overweight, Foundayo reduced breathing interruptions during sleep by up to an average of 44%, with up to 32% of participants achieving remission or mild disease Foundayo also reduced sleep apnea-specific hypoxic burden by up…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPhase 3 data expand Foundayo's potential beyond weight loss, a positive read-through for Lilly shares.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Foundayo reduced breathing interruptions during sleep by up to 44% on average.
- 02The drug cut sleep apnea hypoxic burden by up to 55.9% on average.
- 03Lilly plans to submit to the FDA for moderate-to-severe OSA by end of 2026.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets